AUSUPREME2031.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, AUSUPREME (2031.HK) trades at a P/E of 9.89x, P/B of 1.73x, P/S of 1.23x, and a dividend yield of 4.12%.
Longitudinal percentile comparison: P/E sits at the 26th percentile over the trailing 10Y window (vs. 74th percentile over 3Y); P/B sits at the 69th percentile over the trailing 10Y window (vs. 97th percentile over 3Y); P/S sits at the 54th percentile over the trailing 10Y window (vs. 97th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 30th percentile within its industry and the 45th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 4.12%, ranking at the 46th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 43.1 points apart — worth checking the full percentile matrix on this page for the complete picture. The P/E percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. AUSUPREME operates in the Other Pharmaceuticals and Medical Services sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 2031 · SEHK: 2031 · 2031
Want the full picture on whether AUSUPREME (2031.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 9.89 | ||||||
| P/B (MRQ) | 1.73 | ||||||
| P/S (TTM) | 1.23 | ||||||
| Dividend Yield | 4.12% | ||||||
| Buyback + Div Yield | 4.12% |